Leveraging the active conformation of LFA-1 as a potential target for hematological malignancies.

Current therapeutic strategies for non-Hodgkin's lymphomas (NHLs) and chronic lymphocytic leukemia (CLL) are limited by systemic toxicity, acquired resistance, and tumor-mediated immune suppression. To address these challenges, we introduce a novel nano-liposomal (NP) delivery system that exploits the overexpressed, open-active conformation of lymphocyte function-associated antigen-1 (LFA-1) on malignant hematopoietic cells. This approach facilitates the selective delivery of Wiskott-Aldrich syndrome (WAS)-specific short interfering RNA (siRNA) to lymphoma and leukemia cells. Compared to conventional therapies, our LFA-1-targeted NP system provides a significant advantage by enhancing cell-specific delivery, thereby minimizing off-target effects and potentially reducing systemic toxicity. LFA-1-targeted nanoparticles facilitated the precise delivery of WAS siRNA, resulting in potent inhibition of cytoskeletal-mediated oncogenesis. In vitro assays using patient-derived NHL and CLL cells confirmed significant reductions in proliferation, migration, and invasive capacity. These findings were further validated in vivo, where the targeted delivery system effectively suppressed tumor growth in a human B-NHL xenograft model. This targeted delivery strategy offers a precision approach to gene silencing in hematologic malignancies, potentially improving therapeutic efficacy and reducing adverse effects compared to current non-selective treatments for hematological malignancies, including B-NHL and CLL.